Physician profile
James W Ehlich
NPI 1225010887
$27,008.46
in general payments reported to CMS, 2019-2025
27 companies · $3,265 in 2025
The $3,265 reported for 2025 was more than what 79% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $2,630 · 2021: $839 · 2022: $1,403 · 2023: $2,437 · 2024: $2,438 · 2025: $3,265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,807 · Education: $333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,806.80 |
| Education | $333.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $15,198.13 | 2019-2025 | |
| Amgen INC. | $2,228.84 | 2019-2025 | Krystexxa, Evenity, Tavneos |
| Novartis Pharmaceuticals Corporation | $1,587.31 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,235.55 | 2019-2025 | Benlysta |
| Ucb, INC. | $1,157.27 | 2019-2025 | Bimzelx, Cimzia |
| Horizon Therapeutics Plc | $875.83 | 2019-2023 | Krystexxa |
| Janssen Biotech, INC. | $837.31 | 2019-2025 | Tremfya, Simponi Aria |
| Boehringer Ingelheim Pharmaceuticals, INC. | $638.99 | 2019-2025 | |
| Radius Health, INC. | $545.45 | 2019-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $451.37 | 2021-2024 | Saphnelo |
| Pfizer INC. | $403.82 | 2019-2025 | |
| Lilly USA, LLC | $360.18 | 2019-2025 | Zepbound, Taltz |
| Aurinia Pharma U.S., INC. | $275.42 | 2022-2025 | Lupkynis |
| Genentech USA, INC. | $214.89 | 2019 | |
| Mallinckrodt Hospital Products INC. | $186.42 | 2020-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $184.35 | 2019 | |
| Genzyme Corporation | $119.74 | 2023 | |
| Pacira Therapeutics, INC. | $113.17 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $82.40 | 2019 | |
| Ferring Pharmaceuticals INC. | $72.69 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $71.64 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $69.82 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $34.67 | 2019-2020 | |
| Sandoz INC. | $21.10 | 2025 | Jubbonti |
| Antares Pharma, INC. | $15.69 | 2020 | |
| Gilead Sciences, INC. | $15.44 | 2020 | |
| Medexus Pharma, INC. | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ehlich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.